July 2018
Volume 59, Issue 9
ARVO Annual Meeting Abstract  |   July 2018
Objective Evaluation of FECD: Towards Clinical Trials
Author Affiliations & Notes
  • Sanjay V. Patel
    Ophthalmology, Mayo Clinic , Rochester, Minnesota, United States
  • Footnotes
    Commercial Relationships   Sanjay Patel, None
  • Footnotes
    Support  Research to Prevent Blindness; Mayo Foundation
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3919. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sanjay V. Patel; Objective Evaluation of FECD: Towards Clinical Trials. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3919.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : The recent interest in Fuchs endothelial corneal dystrophy (FECD) research has been spurred by conversion to endothelial keratoplasty and the discovery of the trinucleotide repeat expansion genetic abnormality. These have created new opportunities for managing the disease by modifying surgical approaches and offering the possibility of targeted medical therapy. Implementing new and innovative treatments for FECD will require clinical trials with a standardized approach to the assessment of disease severity and clinical outcomes. This presentation will review classification and grading of FECD, the need for objective evaluation of disease severity, and ideal outcome measures for quantifying success.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.